Skip to main content
Clinical Trials/NCT05219708
NCT05219708
Completed
Not Applicable

Impact of a High Energy and High Protein Nutrition Supplementation Intervention on Outcomes in Patients With Advanced Heart Failure

Columbia University1 site in 1 country33 target enrollmentApril 5, 2022
ConditionsHeart Failure

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Heart Failure
Sponsor
Columbia University
Enrollment
33
Locations
1
Primary Endpoint
Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) Score
Status
Completed
Last Updated
last year

Overview

Brief Summary

In this study, the investigators will determine the impact of a high calorie and high protein nutrition supplementation strategy on quality of life in participants with advanced heart failure. The investigators hypothesize that participants with advanced heart failure who receive the high calorie high protein nutrition supplementation strategy will experience an improvement in quality of life compared to those patients that receive usual care.

Detailed Description

This is a single center, prospective randomized open with blinded endpoint (PROBE) trial with an individual follow-up time of 30 days duration designed to determine the impact of a high calorie high protein nutritional supplementation strategy on quality of life and functional outcomes in adults with malnutrition advanced systolic heart failure. 48 participants will be randomized in a stratified fashion by gender and Subjective Global Assessment (SGA) class (B versus C). Study subjects will receive a calorie and protein nutritional supplement, Ensure Original, manufactured by Abbott laboratories for 30 days after hospital discharge. The study site will be Columbia University Irving Medical Center. Investigators will be blinded to group assignment and dietary recalls until the completion of the study.

Registry
clinicaltrials.gov
Start Date
April 5, 2022
End Date
June 30, 2024
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Mathew S. Maurer, MD

Professor of Cardiology

Columbia University

Eligibility Criteria

Inclusion Criteria

  • Patients aged ≥ 18 years
  • Hospitalized at Columbia University Irving Medical Center/New York Presbyterian Hospital
  • Left ventricular ejection fraction \<=40%
  • At least mild malnutrition as determined by the Subjective Global Assessment (SGA)

Exclusion Criteria

  • Inability to eat orally
  • Inability to eat independently
  • History of dysphagia
  • Allergy to nutritional supplement
  • Need for inotrope and/or mechanical support at hospital discharge
  • Listed for heart transplant
  • Insulin dependent diabetes and/or most recent A1c \>7%
  • Having two or more results of a serum potassium \>5.0 mmol/L during hospitalization or history of serum potassium \>6.0 mmol/L, and/or at an excessive risk of hyperkalemia as judged by the investigators
  • Severe renal insufficiency (estimated glomerular filtration rate \<30 ml/min/1.73m\^2 at discharge)
  • Cirrhosis

Outcomes

Primary Outcomes

Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) Score

Time Frame: Up to 30 days

The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a self-administered questionnaire to assess quality of life in heart failure. Scores range from 0-100 with a higher score indicating better quality of life.

Study Sites (1)

Loading locations...

Similar Trials